Sign up for Table of Contents Alerts.

Email this page

Print this page

Editor's Corner

Cover Image

NA

Hedgehog signaling has been implicated to play an important role in numerous tumors and efforts have been directed at targeting this pathway in therapy using the agent cyclopamine. The Cover Image features work by Patil et al. (in this issue) that for the first time provides evidence hedgehog signaling may be activated in some hepatocellular carcinoma (HCC) tumors and may be a new candidate for therapeutic targeting in HCC. The authors demonstrated via BrdU labeling that cyclopamine inhibited HCC cell growth. Approximately 50-60% of the cells were BrdU positive in SK-Hep1 DMSO treated cells (not shown), whereas only about 10-15% of the cells were BrdU positive in the cyclopamine treated cells (cover image).